Laura Shawver was the ex-CEO of Synthorx Inc, which was bought out by Sanofi for USD2.5bn.
Synthorx Inc is a clinical-stage biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders.
After an USD88m payout, she has joined Silverback Therapeutics as CEO.
Silverback Therapeutics is working on a next-gen antibody drug conjugate. Laura is now in charge of steering that program to the clinic, where it will be tested in HER2 positive cancers.
Copyright © Track Record